1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Synergy Flaunts Constipation Data From Linzess Challenger

 
• By Sukaina Virji

Synergy Pharmaceuticals, which is waiting on a decision from the US FDA on its constipation drug plecanatide, provided additional data from two pivotal Phase III trials at Digestive Disease Week (DDW) in San Diego recently. The product will go up against Linzess, which is marketed by Allergan and Ironwood Pharmaceuticals, and is expected to compete on its better side effect profile.

Constipation
• Source: Shutterstock

Synergy Pharmaceuticals Inc.filed for FDA approval in January this year for the once-daily tablet plecanatide, a uroguanylin analog, as a treatment for chronic idiopathic constipation (CIC). The NDA has been accepted for FDA review with a PDUFA target action date of January 29, 2017.

The plecanatide NDA was supported by two double-blind placebo-controlled Phase III trials (Study-00 and Study-03) and one open-label long term...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Amylyx’s Late-Stage Drug Fails In PSP, But Focus Remains On Avexitide

 
• By Jessica Merrill

The drug that was once commercialized as Relyvrio for ALS failed to show a benefit in adults with progressive supranuclear palsy.

Norway’s Nykode Upbeat About Cancer Vaccines After Tough Year

 
• By Kevin Grogan

The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.

Lilly’s Orforglipron Makes Strong Showing In Diabetic Obesity Population

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III ATTAIN-2 trial in overweight/obese patients with type 2 diabetes and plans to file for approval.

Regeneron Plans To File Cemdisiran For gMG But Will Face Tough Market

 
• By Jessica Merrill

Head of hematology clinical development Andres Sirulnik talked to Scrip about the positive Phase III results for the siRNA medicine.

More from R&D

Lilly’s Orforglipron Makes Strong Showing In Diabetic Obesity Population

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III ATTAIN-2 trial in overweight/obese patients with type 2 diabetes and plans to file for approval.

Regeneron Plans To File Cemdisiran For gMG But Will Face Tough Market

 
• By Jessica Merrill

Head of hematology clinical development Andres Sirulnik talked to Scrip about the positive Phase III results for the siRNA medicine.

Novartis Signs Up For BioArctic Blood-Brain Barrier Tech

 
• By Kevin Grogan

The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.